Bristol Myers Squibb

“Stay grounded on what the ultimate objective is.” Chris Boerner shares his advice on how he leads with perseverance and strength through times of transformation in the first episode of our Trials to Transformation series. #TrialstoTransformation #OneBMS

Ska du till Vitalis? Missa då inte detta seminarium om decentraliserad cancervård som arrangeras av All.Can Sverige, ett nätverk som vi på BMS är med och stöttar. #BMSSverige #Cancer #AllCanSverige

The FDA-approval of our dual immunotherapy as a first-line treatment option for certain patients with hepatocellular carcinoma builds on the BMS legacy of delivering innovative medicines. https://bit.ly/4jcVtXA

Scientists know firsthand the excitement and hope inspired by a potential breakthrough. Our teams continue to push the boundaries of drug discovery and development, from targeted protein degradation and CAR T cell therapy to our application of AI and machine learning. Explore our science through the eyes of our R&D experts: https://bit.ly/4jhxGFw #OneBMS

We are excited to announce our new video series, Trials to Transformation, where our CEO Chris Boerner speaks with leaders to share stories of how moments of challenge and failure can lead to personal and professional transformation and impact. The first episode featuring EVP, Chief Research Officer, Head of Research, Dr. Robert Plenge delves into the pace and power of AI in today’s world. #TrialstoTransformation #OneBMS

We’re working to reimagine the patient experience by providing a continuum of care in #Alzheimers disease. Our focus includes researching investigational medicines that may slow or stop progression to those that better manage symptoms, addressing both sides of Alzheimer’s disease with distinct scientific approaches. Explore more about how we’re pursuing the next generation of treatment options through an agile, dual approach: https://bit.ly/4cdB6GY #ADPD2025 #OneBMS

Our scientists are collaborating with Johnson & Johnson Innovative Medicine to find new ways to improve the risk-benefit profile in treatment of thrombotic events for more patients. Together, our combined dedication to advance cardiovascular care continues to power our Phase 3 Librexia program. As we join our industry peers at #ACC25, our Factor XIa research is a key focus. Learn more about our efforts: https://bit.ly/41Yz7Tz

At #SIRS2025, we’re presenting our latest findings in #schizophrenia research. Explore how we are developing innovative treatments to address the complex needs of people living with serious mental health conditions. This is part of our ongoing commitment to advancing research in #neuroscience. Learn more: https://bit.ly/4iSLWoq #OneBMS

“We need to learn to be a future-ready workforce.” See memorable moments from our immersive #WomensHistoryMonth Keynote Session, including a conversation about building resilience and high-performing teams in the age of AI, hosted by the BMS Network of Women (B-NOW) Global Lead Carla Daily with Lynelle Hoch, President, Cell Therapy Organization, Sydney Klein, Chief Information Security Officer, and Amanda Poole, Chief People Officer, plus a keynote by teamwork expert Erica Dhawan. Join us in celebrating our female colleagues who are fueling innovation for patients and our allies who foster a supportive and empowering environment for all women at BMS. #OneBMS